Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130)
Fast, easy summary view of NICE guidance on 'rheumatoid arthritis'
This guidance recommends adalimumab, etanercept and infliximab as possible treatments for people with rheumatoid arthritis who:
- have already tried methotrexate and another disease-modifying anti-rheumatic drug (DMARD), and
- have 'active' rheumatoid arthritis, as assessed by a rheumatologist on two separate occasions. People who are treated with adalimumab, etanercept or infliximab should normally also be given methotrexate. If methotrexate does not suit them, they may be given adalimumab or etanercept on its own.
This guidance partially updates and replaces NICE technology appraisal 36 (published in March 2002). This review and re-appraisal has additionally included adalimumab for the treatment of rheumatoid arthritis, and has taken into account changes in the marketing authorisations for infliximab and etanercept.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: rheumatoid arthritis
This page was last updated: 07 March 2014
Information for the public
Implementation tools and resources
- Audit support
- Costing template
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology commissioning guide
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.